Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| RADX | Radiopharm Theranostics | $10.63 | $6.37 | 149.53% | 36.2M | $40M | $3.50$16.25 |
| ARTV | Artiva Biotherapeutics | $6.30 | $3.00 | 90.91% | 45.9M | $81M | $1.47$11.55 |
| KXIN | Kaixin | $4.44 | $1.12 | 33.73% | 2.3M | $20M | $2.94$75.00 |
| ASTI | Ascent Solar Technologies | $4.17 | $1.05 | 33.65% | 5.2M | $11M | $1.10$4.60 |
| KYTX | Kyverna Therapeutics | $10.82 | $2.04 | 23.23% | 18.7M | $385M | $1.78$13.67 |
| FGEN | FibroGen | $10.04 | $1.66 | 19.81% | 336K | $34M | $4.85$21.94 |
| RKLZ | Tidal Trust II - Defiance Daily Target 2x Short Rklb ETF | $10.06 | $1.66 | 19.77% | 1.1M | - | $7.50$25.51 |
| QBTZ | Tidal Trust II - Defiance Daily Target 2x Short Qbts ETF | $15.25 | $2.36 | 18.31% | 2.4M | - | $8.77$32.28 |
| SVRE | SaverOne 2014 | $3.54 | $0.54 | 18.00% | 1.5M | $2.2M | $2.31$190.75 |
| RGTZ | Tidal Trust II - Defiance Daily Target 2x Short Rgti ETF | $22.57 | $3.40 | 17.74% | 5M | - | $8.14$37.48 |
Related Articles
Featured Article
This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
Leo Miller|Aug 29, 2024
Artiva's revolutionary cell therapies could be a patient lifeline and a goldmine for investors.
Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?
Alex Carchidi|Feb 25, 2024
The market's excited for these stocks, but there's no rush to buy them.
Down 80% in 1 Day, Is There Any Hope for FibroGen Stock?
Alex Carchidi|Jul 1, 2023
Its pipeline is looking thin, and it might hit another speed bump quite soon.
Advertisement
Is It Too Late to Buy Rent the Runway Stock?
Leo Sun|Dec 10, 2022
The apparel rental marketplace could be on the cusp of a comeback.
Buying This IPO Could Be a Big Mistake
Asit Sharma, CPA|Nov 9, 2021
Rent the Runway is looking to invent a cloud-based wardrobe for fashionistas across the world, but its business is already looking shabby.
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
Keith Speights|Jul 29, 2021
FDA approval of roxadustat seems unlikely.
FibroGen's Anemia Drug Goes to FDA for Review
Eric Volkman|Feb 12, 2020
A decision on Roxadustat should arrive by Dec. 20.
FibroGen Appoints Enrique Conterno as Its New CEO
Brian Orelli, PhD|Jan 6, 2020
The former Eli Lilly executive will be tasked with launching the biotech's anemia drug roxadustat.
![Enrique-Conterno[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F552569%2Fenrique-conterno1.jpg&w=384&op=resize)
Here’s Why FibroGen’s Stock Popped Friday
David Haen|Nov 11, 2019
FibroGen reported highly anticipated clinical data on Friday for its lead drug roxadustat in chronic kidney disease.
4 Biotech Stocks With Major Catalysts in April
Cory Renauer|Apr 2, 2019
April's about to shower biopharma investors with important updates that could move these stocks.
